Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpointsIbrexafungerp was generally safe and […]
BOSTON, April 21, 2020 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today […]